Three Small-Cap European Stocks Flying Under the Radar This May
European equities have been treading water lately. The STOXX Europe 600 is up modestly, but beneath the surface, a quiet rotation is underway. With interest rates holding steady and sentiment swinging between cautious and optimistic, attention is shifting toward smaller companies that can move faster and adapt more nimbly than their larger peers.
For investors willing to look beyond the usual suspects, there are opportunities in corners of the market that don't always make headlines. Below, we highlight three European small-caps that have recently shown strong earnings momentum, solid fundamentals, and—in some cases—strategic moves that could pay off over the long haul.
Gabler Group AG: A Submarine Specialist Surfaces
Market Cap: €221.43 million | Simply Wall St Value Rating: ★★★★☆☆
Gabler Group isn't a household name, but it plays a critical role in defense and underwater technology. The company designs and manufactures hoistable masts and components for submarines, and it recently completed an IPO that raised €115.5 million—a strong signal of investor appetite.
Earnings have more than doubled over the past year, jumping from €2.94 million to €6.75 million, while sales climbed to €70.72 million from €49.36 million. Despite that growth, Gabler trades at a price-to-earnings ratio of 38x—well below the Aerospace & Defense industry average of 58x. That valuation gap suggests room for upside, even if the stock has seen some volatility since listing.
“An IPO is always a gamble, but Gabler’s niche is hard to replicate. If defense budgets keep rising, this could be a quiet winner,” says Markus Lehmann, a Frankfurt-based portfolio manager.
BioGaia AB: Probiotics With a Balance Sheet to Match
Market Cap: SEK 12.09 billion | Simply Wall St Value Rating: ★★★★★★
BioGaia is a Swedish healthcare company focused on probiotics for gut, oral, and immune health. It has been debt-free for five years, and its earnings quality is rated as high—a rarity in the biotech space.
While earnings dipped 5.3% last year, the company is expanding aggressively into North America and forging new partnerships across Europe. Its flagship product, Limosilactobacillus reuteri Protectis®, continues to gain scientific backing, and analysts project annual revenue growth of 10% as global demand for natural health products rises.
“I’ve been burned by health stocks before, but BioGaia’s balance sheet is rock solid. No debt, real revenue, and a product people actually buy. That’s more than I can say for half the companies in this space,” says Clara Johansson, a retail investor from Stockholm who follows the stock closely.
Studsvik AB: Nuclear Services With a Growth Spark
Market Cap: SEK 2.35 billion | Simply Wall St Value Rating: ★★★★☆☆
Studsvik provides technical solutions for the nuclear and radioactive materials sector, operating across Sweden, Germany, Asia, and North America. Its earnings surged 233.5% over the past year, far outpacing industry averages, and its net debt-to-equity ratio sits at a comfortable 19.8%.
The company has also formed strategic alliances with Rolls-Royce SMR and Novatron Fusion Group, positioning itself at the forefront of next-generation nuclear technology. Still, Q1 sales slipped slightly to SEK 226 million from SEK 227 million, and net income fell to SEK 4.5 million from SEK 8.8 million—a reminder that growth isn't always linear.
“Studsvik is riding the nuclear renaissance wave, but the Q1 numbers give me pause. If they can’t convert hype into consistent earnings, the stock could get choppy,” says Thomas Andersson, an energy analyst at a Nordic investment firm.
This article is for informational purposes only and does not constitute financial advice. Always conduct your own research before making investment decisions.